TruBridge Announces Participation in the Stifel Cross Sector Insight Conference

2 years ago

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, today announced that management will participate in the Stifel Cross Sector…

GRM Information Management to Attend the 2024 MUSE Inspire Conference

2 years ago

Visit GRM Information Management in Booth #125 at the 2024 MUSE Inspire Conference in Denver, CO May 28-31JERSEY CITY, N.J.--(BUSINESS…

cbdMD Unveils ATRx Labs Premium Mushroom Line at GNC, Expanding cbdMD’s Natural Wellness Solutions

2 years ago

Charlotte, North Carolina--(Newsfile Corp. - May 24, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA) (the "Company") is…

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

2 years ago

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with…

Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework

2 years ago

ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

2 years ago

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T…

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

2 years ago

CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic…

Monopar Announces CFO Succession

2 years ago

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing…

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

2 years ago

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free…